GA-map Dysbiosis Test Lx
Commercial- Indications
- IBS, IBD
Company intelligence / Profile preview
Genetic Analysis AS has developed and commercialized the GA-map® platform for standardized gut microbiota analysis. Their CE-marked diagnostic test enables clinicians to profile the human gut microbiome and identify dysbiosis associated with gastrointestinal disorders. The company’s technology has been validated in clinical studies and adopted by research institutions and healthcare providers.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Genetic Analysis.